➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Medtronic
Dow
Baxter
Johnson and Johnson
AstraZeneca

Last Updated: July 12, 2020

DrugPatentWatch Database Preview

NORTHERA Drug Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

When do Northera patents expire, and what generic alternatives are available?

Northera is a drug marketed by Lundbeck Na Ltd and is included in one NDA.

The generic ingredient in NORTHERA is droxidopa. There are six drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the droxidopa profile page.

Drug patent expirations by year for NORTHERA
Drug Prices for NORTHERA

See drug prices for NORTHERA

Generic Entry Opportunity Date for NORTHERA
Generic Entry Date for NORTHERA*:
Constraining patent/regulatory exclusivity:
TREATMENT OF NEUROGENIC SYMPTOMATIC ORTHOSTATIC HYPOTENSION IN PATIENTS WITH PRIMARY AUTONOMIC FAILURE, DOPAMINE-BETA-HYDROXYLASE DEFICIENCY, AND NONDIABETIC AUTONOMIC NEUROPATHY
NDA:
Dosage:
CAPSULE;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for NORTHERA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Lundbeck LLCPhase 4
William Ondo, MDPhase 4
Arizona State UniversityPhase 2

See all NORTHERA clinical trials

Pharmacology for NORTHERA
Physiological EffectIncreased Blood Pressure

US Patents and Regulatory Information for NORTHERA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lundbeck Na Ltd NORTHERA droxidopa CAPSULE;ORAL 203202-001 Feb 18, 2014 RX Yes No   Start Trial   Start Trial   Start Trial
Lundbeck Na Ltd NORTHERA droxidopa CAPSULE;ORAL 203202-002 Feb 18, 2014 RX Yes No   Start Trial   Start Trial   Start Trial
Lundbeck Na Ltd NORTHERA droxidopa CAPSULE;ORAL 203202-003 Feb 18, 2014 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Medtronic
Dow
Baxter
Johnson and Johnson
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.